MIcrovascular dysfuNction In Moderate-severe Psoriasis
Recruiting
Marcelo F. Di Carli, MD, FACC
Phase 4
2020-08-04
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the
population, is associated with increased cardiovascular (CV) risk. Despite the implication of
inflammation in this excess risk, it remains unclear whether reducing inflammation reduces
the risk of cardiac events. This study proposes to test whether Tildrakizumab, an FDA
approved therapy for psoriasis that blocks IL-23 and the Th17 pathway of inflammation,
improves coronary vascular function and coronary flow reserve, as measured by noninvasive
imaging with cardiac positron emission tomography. In so doing, improvement in coronary
vasoreactivity, endothelial function, and tissue perfusion may have beneficial effects on
myocardial mechanics, left ventricular deformation and function and, ultimately, symptoms and
prognosis.
This research may offer novel insights into the contributors of CV risk in psoriasis and
provide data to support the development of strategies to prevent cardiovascular events in
psoriatic disease.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
